Abstracts Archive - Page 2372 of 2425 - ACR Meeting Abstracts

Abstract Number: 737 • 2012 ACR/ARHP Annual Meeting
Citrullination of ENA-78/CXCL5 Results in Conversion From a Non-Monocyte Recruiting to a Monocyte Recruiting Chemokine
Ken Yoshida¹, Olex Korchynskyi², Paul P. Tak³, Takeo Isozaki⁴, Jeffrey H. Ruth⁵, Phillip Campbell⁶, Dominique L. Baeten⁷, Danielle M. Gerlag⁷, M. Asif Amin⁸ and Alisa E. Koch⁹, ¹Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ²Department of Cellular Proliferation and Apoptosis, Institute of Cell Biology, Lviv, Ukraine, ³Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁶Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁷Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁸Department of Medicine, University of Michigan, Ann Arbor, MI, ⁹Internal Medicine - Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Citrullination is a post-translational modification that is the conversion of arginine to citrulline in proteins mediated by peptidylarginine deiminase (PAD). Antibodies directed towards the…
Abstract Number: 738 • 2012 ACR/ARHP Annual Meeting
A Novel Orally Active Phosphatidylinositol 3-Phosphate 5-Kinase (PIKfyve) Inhibitor Ameliorates Mouse Psoriasis-Like Model by Inhibition of Interleukin-12 and Interleukin-23 Production From Macrophages
Ayatoshi Andou, Eviryanti Agung, Yukie Seki, Yoichiro Shima, Sen Takeshita, Takashi Yamamoto and Hiroyuki Eda, Exploratory Research Laboratories, Ajinomoto Pharmaceuticals Co., Ltd., Kanagawa, Japan
Background/Purpose: Phosphatidylinositol (3,5)-bisphosphate (PI(3,5)P2) is the most recently-identified phospholipid component of cellular membrane. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is a critical enzyme for the synthesis of…
Abstract Number: 739 • 2012 ACR/ARHP Annual Meeting
The Serine Arginine Protein SF2/ASF Is a Novel Regulator of IL-2 Transcription and Restores IL-2 Production in T Lymphocytes From SLE Patients
Vaishali R. Moulton¹, Alexandros P. Grammatikos¹ and George C. Tsokos², ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease which afflicts mainly women in the reproductive years, and causes painful arthritis, skin disease and…
Abstract Number: 740 • 2012 ACR/ARHP Annual Meeting
Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification
Melissa E. Munroe¹, Jourdan R. Anderson², Julie M. Robertson³, Timothy B. Niewold⁴, George C. Tsokos⁵, Michael P. Keith⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁷Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized. Several cytokines have been associated…
Abstract Number: 741 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Recurrent Gout Attacks During Hospitalization
Yuqing Zhang¹, Clara Chen², Hyon K. Choi³, Christine E. Chaisson², David J. Hunter⁴ and Tuhina Neogi⁵, ¹Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁵Clinical Epidemiology, Boston Univ Schl of Med, Boston, MA
Background/Purpose: While anecdotal evidence suggests that risk of recurrent gout attack increases during hospitalization and gout is one of the most common reasons for in-patient…
Abstract Number: 742 • 2012 ACR/ARHP Annual Meeting
Utility of HLA-B5801 Genotyping and Renal Dosing of the Starting Dose of Allopurinol in Preventing Allopurinol Hypersensitivity Syndrome: A Cost-Effectiveness Analysis
Yanyan Zhu¹, Ada Man², Tuhina Neogi³ and Hyon K. Choi⁴, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy (~ 95%) for gout which affects 8.3 million US adults. However, allopurinol is associated with a…
Abstract Number: 743 • 2012 ACR/ARHP Annual Meeting
Anemia and the Onset of Gout in a Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study
Mara McAdams DeMarco¹, Janet W. Maynard², Josef Coresh¹ and Alan N. Baer³, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Rheum/Mason F Lord Bldg/CtrTow, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There is a growing prevalence of gout in the US and worldwide. Gout is a recognized risk factor for cardiovascular disease (CVD). It is…
Abstract Number: 744 • 2012 ACR/ARHP Annual Meeting
Racial Differences in Reported Knee Pain Severity Persist Even After Adjustment for Knee Examination and Radiographic Findings: Data From the Osteoarthritis Initiative
Paige Luneburg¹, Laura Yerges-Armstrong², Braxton D. Mitchell² and Marc C. Hochberg¹, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: African Americans have a higher prevalence of both radiographic and symptomatic radiographic knee osteoarthritis (OA) than Caucasians. In addition, African Americans with knee OA…
Abstract Number: 745 • 2012 ACR/ARHP Annual Meeting
Soft Drink Intake and Progression of Radiographic Knee Osteoarthritis: Data From the Osteoarthritis Initiative
Bing Lu¹, Jeffrey Driban², Tim McAlindon³ and Charles Eaton⁴, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Tufts Medical Center, MA, ³Tufts Medical Center, Boston, MA, ⁴Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI
Soft Drink Intake and Progression of Radiographic Knee Osteoarthritis: Data from the Osteoarthritis InitiativeBackground/Purpose : Soft drink consumption has been associated with weight gain and…
Abstract Number: 746 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Acute and Chronic Renal Comorbidity in Ankylosing Spondylitis: Results From a Population-Based Study
Walter P. Maksymowych¹, Shelagh Szabo², Sumati Rao³, Mary A. Cifaldi³ and Adrian R. Levy⁴, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Oxford Outcomes, Oxford Outcomes, Vancouver, BC, Canada, ³Abbott Laboratories, Abbott Park, IL, ⁴Oxford Outcomes Ltd, Vancouver, BC, Canada
Background/Purpose: Clinical evidence points to an increased risk of renal comorbidity in ankylosing spondylitis (AS) compared to the general population. However, there are no population-based…
Abstract Number: 747 • 2012 ACR/ARHP Annual Meeting
Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome.
Nicola Stein¹, Matthias Witt², Michael Baeuerle³, Fabian Proft¹, Hendrik Schulze-Koops⁴ and Mathias Gruenke¹, ¹Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ²Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ³Division of Rheumatology, Klinikum Nürnberg, Nuernberg, Germany, ⁴University of Munich, Munich, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is the most prevalent episodic fever syndrome with more than 100.000 affected individuals worldwide. Colchicine is the established first-line therapy…
Abstract Number: 748 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Cryopyrin Associated Periodic Syndrome: Results From Meta-Analysis of 5 Studies
Helen J. Lachmann¹, Jasmin B. Kuemmerle-Deschner², Toshio Heike³, Toshiro Hara⁴, Shumpei Yokota⁵, Phil Mckernan⁶, Albert Widmer⁶, Nicole Davis⁷ and Eric Hachulla⁸, ¹UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ²University Hospital Tuebingen, Tuebingen, Germany, ³Department of Pediatrics, Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Pediatrics, Department of Pediatrics, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan, ⁵Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Department of Internal Medicine, Claude Huriez University Hospital, Lille, France
Background/Purpose: Canakinumab (CAN) is approved in over 60 countries for the treatment of CAPS. This meta-analysis evaluated the efficacy and safety of CAN and assessed…
Abstract Number: 749 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with TNF Receptor Associated Periodic Syndrome
Marco Gattorno¹, Laura Obici², Antonella Meini³, Vincent Tormey⁴, Ken Abrams⁵, Nicole Davis⁵, Christopher Andrews⁶ and Helen J. Lachmann⁷, ¹Second Division of Paediatrics, Istituto Giannina Gaslini, Genova, Italy, ²Amyloid Centre, IRCCS Policlinico San Matteo, Pavia, Italy, ³Pediatric Clinic, University of Brescia and Spedali Civili di Brescia, Pediatric Immunology and Rheumatology, Brescia, Italy, ⁴Galway University Hospitals, Galway, Ireland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, ⁷UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom
Background/Purpose: TNF-receptor associated periodic syndrome (TRAPS) is a rare dominantly inherited periodic fever syndrome due to mutations of the TNFRSF1A gene. It is characterized by…
Abstract Number: 750 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Adults with Colchicine Resistant Familial Mediterranean Fever
A. Gul¹, H. Ozdogan², B. Erer³, S. Ugurlu², Nicole Davis⁴, S. Sevgi⁵ and O. Kasapcopur⁶, ¹Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Novartis Pharma Corp, East Hannover, ⁵Novartis Pharma, Istanbul, Turkey, ⁶Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is associated with variations in the MEFV gene resulting in proteolytic activation of IL-1β through the inflammasome complex. FMF is…
Abstract Number: 751 • 2012 ACR/ARHP Annual Meeting
Whole Transcriptome Analysis in Erdheim-Chester Disease: A Multicenter Collaborative Study of 58 Patients
Laurent Arnaud¹, Julien Haroche², Lorenzo Dagna³, Augusto Vaglio⁴, Bruno Faivre⁵, Karim Dorgham⁵, Baptiste Hervier⁶, Fleur Cohen-Aubart⁷, Guy Gorochov⁸ and Zahir Amoura¹, ¹Internal Medicine, Hopital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, ²Department of Internal Medicine 2. Referal center for SLE/APS, Hopital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, ³Vita-Salute San Raffaele University, Milan, Italy, ⁴Unit of Nephrology, University Hospital of Parma, Parma, Italy, ⁵Institut National de la Santé et de la Recherche Médicale, INSERM UMR-S 945, Paris, France, ⁶Internal Medicine I & II, Hopital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, ⁷Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁸Inserm UMRS945, Institut National de la Santé et de la Recherche Médicale, INSERM UMR-S 945, Paris, France
Background/Purpose: To date, gene expression profiling has not been performed in Erdheim-Chester disease (ECD), a rare, non-Langerhans form of histiocytosis. The aim of this study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].